Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sectra ABCHIX:SECTBS +0.14%99 Revenue per Share is kr18.38 as of Apr. 2026. GuruFocus rates CHIX:SECTBS with a GF Score™ of 99/100 and a GF Value™ of kr315.00 (Modestly Undervalued). Among 754 Medical Devices & Instruments companies, Sectra AB ranks better than 76.92% on this metric.
Sectra AB's revenue per share for the
three
months ended in Apr. 2026 was kr5.36.
Sectra AB's revenue per share for the trailing twelve months (TTM) ended in Apr. 2026 was kr18.38.
Good Sign:
Sectra AB has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue Per Share Growth Rate of Sectra AB was 9.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 14.70% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 17.50% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 13.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Sectra AB's Revenue per Share or its related term are showing as below:
CHIX:SECTBs'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.2 Med: 9.5 Max: 22
Current: 14.7
During the past 13 years, Sectra AB's highest 3-Year average Revenue Per Share Growth Rate was 22.00% per year. The lowest was -3.20% per year. And the median was 9.50% per year.
CHIX:SECTBs's 3-Year Revenue Growth Rate is ranked better than 76.92% of 754
companies
in the Medical Devices & Instruments industry
Industry Median: 3.7
vs CHIX:SECTBs: 14.70
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Sectra AB Revenue per Share Related Terms
Sectra AB Revenue per Share Historical Data
* Premium members only.
The historical data trend for Sectra AB's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SECTBS vs ABT, SYK, MDT: Revenue per Share Comparison
For the Medical Devices subindustry, Sectra AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sectra AB PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sectra AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sectra AB's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Sectra AB's Revenue Per Share for the fiscal year that ended in Apr. 2026 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr18.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sectra AB (CHIX:SECTBS) has a Revenue per Share of kr18.38 as of Apr. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Sectra AB and its competitors. According to the industry distribution chart, Sectra AB ranks #174 out of 754 companies in the Medical Devices & Instruments industry, placing it in the top 23.1%.
Is Sectra AB's Revenue per Share too high?
Sectra AB's current Revenue per Share is kr18.38. Based on the distribution chart, Sectra AB ranks #174 out of 754 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sectra AB has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sectra AB's Revenue per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sectra AB ranks #174 out of 754 companies for Revenue per Share. This places Sectra AB in the top 23% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.70, based on 754 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Sectra AB and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sectra AB's current Revenue per Share is kr18.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sectra AB stock overvalued right now?
Based on GuruFocus' analysis, Sectra AB (CHIX:SECTBS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr315.00, compared to a current price of kr279.80 — trading 11.2% below its estimated fair value. The current Revenue per Share is kr18.38. Sectra AB's overall GF Score™ is 99/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Sectra AB (CHIX:SECTBS), the current Revenue per Share is kr18.38 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sectra AB (CHIX:SECTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Sectra AB stock appears to be undervalued.
The current stock price of kr279.80 is trading 11.2% below its estimated GF Value™ of kr315.00.
GuruFocus considers Sectra AB to be Modestly Undervalued.
Key valuation signals for CHIX:SECTBS:
Revenue per Share: kr18.38
GF Value™: kr315.00 vs. price of kr279.80 (11.2% below fair value)
No single metric tells the full story. See the CHIX:SECTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sectra AB develops IT solutions and services for storing, viewing, and working with medical images. The operating business segments are Imaging IT Solutions, Secure Communications, Business Innovation, and Other Operations. It generates maximum revenue from the Imaging IT Solutions segment. The company also offers maintenance in the form of support, system monitoring, and consulting services related to integration, system design, data migration, and business development. Geographically, it derives a majority of its revenue from the United States, followed by Sweden, the United Kingdom, the Netherlands, the Rest of Europe, and the Rest of the world.
99GF Score
Get the complete analysis for CHIX:SECTBS
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SECTBS has been successfully added to your 
